Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when 3 different
IMPs are given as monotherapy or as combination therapy. These would be administered in the
"window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer
Phase:
Phase 2
Details
Lead Sponsor:
CCTU- Cancer Theme
Collaborators:
AstraZeneca Cancer Research UK University of Cambridge